Human Erythropoietin/EPO Antibody

Catalog #: MAB2872 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB2872-100
MAB2872-SP

Cell Proliferation Induced by Erythropoietin/EPO and Neutralization by Human Erythropoietin/EPO Antibody.

1 Image

Product Details

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human Erythropoietin/EPO Antibody Summary

Species Reactivity

Human

Specificity

Detects human Erythropoietin/EPO in direct ELISAs.

Source

Monoclonal Mouse IgG₁ Clone # 971019

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Chinese Hamster Ovary cell line CHO-derived human Erythropoietin/EPO protein
Ala28-Arg193
Accession # CAA26094

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Neutralization

Measured by its ability to neutralize Erythropoietin/EPO-induced proliferation in the TF‑1 human erythroleukemic cell line. Kitamura, T. et al. (1989) J. Cell Physiol. 140:323. The Neutralization Dose (ND₅₀) is typically 0.02-0.2 µg/mL in the presence of 0.3 units/mL Recombinant Human Erythropoietin/EPO (Tissue Culture Grade).

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization

View Larger

Cell Proliferation Induced by Erythropoietin/EPO and Neutralization by Human Erythropoietin/EPO Antibody. Recombinant Human Erythropoietin/EPO (Tissue Culture Grade) (Catalog # 287-TC) stimulates proliferation in theTF-1 human erythroleukemic cell line in a dose-dependent manner (orange line), as measured by Resazurin (Catalog # AR002). Proliferation elicited by Recombinant Human Erythropoietin/EPO (Tissue Culture Grade) (0.3 units/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human Erythropoietin/EPO Monoclonal Antibody (Catalog # MAB2872). The ND₅₀ is typically 0.02-0.2 µg/mL.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Erythropoietin/EPO

Erythropoietin (EPO) is a 34 kDa glycoprotein hormone in the type I cytokine family and is related to thrombopoietin (1). Its three N-glycosylation sites, four alpha helices, and N- to C-terminal disulfide bond are conserved across species (2, 3). Glycosylation of EPO is required for biological activities in vivo (4). Mature human EPO shares 75%-84% amino acid sequence identity with bovine, canine, equine, feline, mouse, ovine, porcine, and rat EPO. EPO is primarily produced in the kidney by a population of fibroblast-like cortical interstitial cells adjacent to the proximal tubules (5). It is also produced in much lower, but functionally significant amounts by fetal hepatocytes and in adult liver and brain (6-8). EPO promotes erythrocyte formation by preventing the apoptosis of early erythroid precursors which express the EPO receptor (EPO R) (8, 9). EPO R has also been described in brain, retina, heart, skeletal muscle, kidney, endothelial cells, and a variety of tumor cells (7, 8, 10, 11). Ligand induced dimerization of EPO R triggers JAK2-mediated signaling pathways followed by receptor/ligand endocytosis and degradation (1, 12). Rapid regulation of circulating EPO allows tight control of erythrocyte production and hemoglobin concentrations. Anemia or other causes of low tissue oxygen tension induce EPO production by stabilizing the hypoxia-induceable transcription factors HIF-1 alpha and HIF-2 alpha (1, 6). EPO additionally plays a tissue-protective role in ischemia by blocking apoptosis and inducing angiogenesis (7, 8, 13).

References